The College of Basic Medical Sciences of Jilin University draws upon its strong disciplinary clusters to drive research excellence. It is home to two Key Laboratories of the Ministry of Education—Pathobiology and Zoonotic Diseases—as well as the Basic Research Innovation Center for Airway Diseases in Northern Cold Regions (Ministry of Education) and the National Medical Products Administration Key Laboratory for the Evaluation of Humanized Animal Models for Vaccines and Cell Therapy Products.

        The college places strong emphasis on systematic and well-planned scientific development. The Airway Diseases Research Center integrates resources from Changchun, Beijing, and Guangzhou to establish a comprehensive research chain spanning basic medical research, drug development, and clinical application, addressing the prevention and control of major diseases in Northeast China. Similarly, the Jilin University Ginseng Innovation Research Institute has set up four R&D centres and two specialised platforms, working with leading enterprises such as Jilin Huakang Pharmaceutical to translate research into industrial applications. Notably, during the COVID-19 pandemic in 2020, the college undertook a national major science and technology project, with its products rapidly deployed to frontline efforts in Wuhan.

        Over the past five years, the college has achieved significant research milestones. It has secured 273 funded projects with a total budget of 87.57 million CNY, including six major projects each exceeding 2 million CNY. These projects span frontier areas such as tumour biology, immune microenvironment regulation, and AI-based drug design. Examples include Research on the Carcinogenic Mechanism of Human Papillomavirus (HPV) (2.988 million CNY) and Iron-Based Composite Materials for Inhibiting Tumour Recurrence (3.3 million CNY), underscoring the college’s capacity to address critical scientific challenges. In addition, the college has been awarded 38 National Natural Science Foundation projects, including 15 general programmes (8.9367 million CNY), 12 youth funds (3.6 million CNY), two international cooperation projects (3.138 million CNY), and three national key R&D programmes (8.7 million CNY), amounting to a total of 28.8047 million CNY.

        Research output has been equally impressive, with 427 SCI-indexed papers published, including 70 in Chinese Academy of Sciences Zone 1 journals and 11 in top-tier journals such as Cell, Signal Transduction and Targeted Therapy, and Advanced Functional Materials. The college has also received six provincial and ministerial-level awards, including the Jilin Provincial Science and Technology Progress Award (Second Prize), the Jilin Provincial Natural Science Award (First Prize), and the Huaxia Medical Science and Technology Award (two First Prizes and two Second Prizes).

        To date, the college has secured 20 invention patents, including two international patents granted in Australia, highlighting its commitment to innovation and translational impact.